Inhibition of human immunodeficiency virus 1 (HIV-1) by variant B of human herpesvirus 6 (HHV-6). 1999

F Bonura, and A M Perna, and F Vitale, and M R Villafrate, and E Viviano, and R Guttadauro, and G Mazzola, and N Romano
Dipartimento di Igiene e Microbiologia G. D'Alessandro, Facoltà di Medicina e Chirurgia, Università degli Studi, Palermo, Italia.

Four HHV-6 strains were initially isolated during attempts to observe HIV-1 replication in cultured primary lymphocytes from 48 patients with AIDS. HHV-6 DNA from each strain was extracted from primary cell cultures and amplified using specific primers in a nested polymerase chain reaction (PCR) assay. All HHV-6 strains were classified as B variants by submitting the PCR products to the digestion of two restriction enzymes (Hind III and Bgl II). Since in primary cultures, the appearance of HHV-6 cytopathic effect was followed by a progressive reduction of HIV-1 replication, we tried to reproduce the observed inhibition in vitro. Two HHV-6 strains, used throughout the experiments, showed their ability to suppress HIV-1 replication when the viruses co-infected CD4+T lymphocyte cultures. While the intrinsic mechanism of this finding still remains unclear, the inhibition of HIV-1 replication was observed only when a high multiplicity of infection (m.o.i.) of HHV-6 and a low m.o.i. of HIV-1 were used in dually infected cell cultures. By using a semiquantitative determination of HIV-1 cDNA by PCR, it appears that the inhibition begins in infected cell cultures and, once established, does not allow any further HIV-1 replication.

UI MeSH Term Description Entries
D012150 Polymorphism, Restriction Fragment Length Variation occurring within a species in the presence or length of DNA fragment generated by a specific endonuclease at a specific site in the genome. Such variations are generated by mutations that create or abolish recognition sites for these enzymes or change the length of the fragment. RFLP,Restriction Fragment Length Polymorphism,RFLPs,Restriction Fragment Length Polymorphisms
D003588 Cytopathogenic Effect, Viral Visible morphologic changes in cells infected with viruses. It includes shutdown of cellular RNA and protein synthesis, cell fusion, release of lysosomal enzymes, changes in cell membrane permeability, diffuse changes in intracellular structures, presence of viral inclusion bodies, and chromosomal aberrations. It excludes malignant transformation, which is CELL TRANSFORMATION, VIRAL. Viral cytopathogenic effects provide a valuable method for identifying and classifying the infecting viruses. Cytopathic Effect, Viral,Viral Cytopathogenic Effect,Cytopathic Effects, Viral,Cytopathogenic Effects, Viral,Effect, Viral Cytopathic,Effect, Viral Cytopathogenic,Effects, Viral Cytopathic,Effects, Viral Cytopathogenic,Viral Cytopathic Effect,Viral Cytopathic Effects,Viral Cytopathogenic Effects
D004279 DNA, Viral Deoxyribonucleic acid that makes up the genetic material of viruses. Viral DNA
D006566 Herpesviridae Infections Virus diseases caused by the HERPESVIRIDAE. Herpesvirus Infections,B Virus Infection,Infections, Herpesviridae,Infections, Herpesvirus,B Virus Infections,Herpesviridae Infection,Herpesvirus Infection,Infection, B Virus,Infection, Herpesviridae,Infection, Herpesvirus,Infections, B Virus
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000163 Acquired Immunodeficiency Syndrome An acquired defect of cellular immunity associated with infection by the human immunodeficiency virus (HIV), a CD4-positive T-lymphocyte count under 200 cells/microliter or less than 14% of total lymphocytes, and increased susceptibility to opportunistic infections and malignant neoplasms. Clinical manifestations also include emaciation (wasting) and dementia. These elements reflect criteria for AIDS as defined by the CDC in 1993. AIDS,Immunodeficiency Syndrome, Acquired,Immunologic Deficiency Syndrome, Acquired,Acquired Immune Deficiency Syndrome,Acquired Immuno-Deficiency Syndrome,Acquired Immuno Deficiency Syndrome,Acquired Immuno-Deficiency Syndromes,Acquired Immunodeficiency Syndromes,Immuno-Deficiency Syndrome, Acquired,Immuno-Deficiency Syndromes, Acquired,Immunodeficiency Syndromes, Acquired,Syndrome, Acquired Immuno-Deficiency,Syndrome, Acquired Immunodeficiency,Syndromes, Acquired Immuno-Deficiency,Syndromes, Acquired Immunodeficiency
D014762 Viral Interference A phenomenon in which infection by a first virus results in resistance of cells or tissues to infection by a second, unrelated virus. Interference, Viral,Interferences, Viral,Viral Interferences
D014779 Virus Replication The process of intracellular viral multiplication, consisting of the synthesis of PROTEINS; NUCLEIC ACIDS; and sometimes LIPIDS, and their assembly into a new infectious particle. Viral Replication,Replication, Viral,Replication, Virus,Replications, Viral,Replications, Virus,Viral Replications,Virus Replications
D015496 CD4-Positive T-Lymphocytes A critical subpopulation of T-lymphocytes involved in the induction of most immunological functions. The HIV virus has selective tropism for the T4 cell which expresses the CD4 phenotypic marker, a receptor for HIV. In fact, the key element in the profound immunosuppression seen in HIV infection is the depletion of this subset of T-lymphocytes. T4 Cells,T4 Lymphocytes,CD4-Positive Lymphocytes,CD4 Positive T Lymphocytes,CD4-Positive Lymphocyte,CD4-Positive T-Lymphocyte,Lymphocyte, CD4-Positive,Lymphocytes, CD4-Positive,T-Lymphocyte, CD4-Positive,T-Lymphocytes, CD4-Positive,T4 Cell,T4 Lymphocyte
D015497 HIV-1 The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte. Human immunodeficiency virus 1,HIV-I,Human Immunodeficiency Virus Type 1,Immunodeficiency Virus Type 1, Human

Related Publications

F Bonura, and A M Perna, and F Vitale, and M R Villafrate, and E Viviano, and R Guttadauro, and G Mazzola, and N Romano
April 1989, Mikrobiyoloji bulteni,
F Bonura, and A M Perna, and F Vitale, and M R Villafrate, and E Viviano, and R Guttadauro, and G Mazzola, and N Romano
January 1989, Journal of virological methods,
F Bonura, and A M Perna, and F Vitale, and M R Villafrate, and E Viviano, and R Guttadauro, and G Mazzola, and N Romano
June 1989, Revue francaise de transfusion et d'hemobiologie : bulletin de la Societe nationale de transfusion sanguine,
F Bonura, and A M Perna, and F Vitale, and M R Villafrate, and E Viviano, and R Guttadauro, and G Mazzola, and N Romano
October 2007, Virology journal,
F Bonura, and A M Perna, and F Vitale, and M R Villafrate, and E Viviano, and R Guttadauro, and G Mazzola, and N Romano
November 1999, Nihon rinsho. Japanese journal of clinical medicine,
F Bonura, and A M Perna, and F Vitale, and M R Villafrate, and E Viviano, and R Guttadauro, and G Mazzola, and N Romano
June 2010, Nihon rinsho. Japanese journal of clinical medicine,
F Bonura, and A M Perna, and F Vitale, and M R Villafrate, and E Viviano, and R Guttadauro, and G Mazzola, and N Romano
December 2010, Uirusu,
F Bonura, and A M Perna, and F Vitale, and M R Villafrate, and E Viviano, and R Guttadauro, and G Mazzola, and N Romano
June 1996, Antiviral research,
F Bonura, and A M Perna, and F Vitale, and M R Villafrate, and E Viviano, and R Guttadauro, and G Mazzola, and N Romano
March 1993, No to hattatsu = Brain and development,
F Bonura, and A M Perna, and F Vitale, and M R Villafrate, and E Viviano, and R Guttadauro, and G Mazzola, and N Romano
October 1990, The Journal of infectious diseases,
Copied contents to your clipboard!